What can be inferred from the interruption of the semagacestat trial for treatment of Alzheimer's disease?
Cummings
Jeffrey
J
Cleveland Clinic Lou Ruvo Center for Brain Health, Cleveland Clinic Neurological Institute, Las Vegas, Nevada 89106, USA. cumminj@ccf.org
D000409:Alanine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000544:Alzheimer Disease / Q000188:drug therapy*; D000682:Amyloid / Q000187:drug effects; D053829:Amyloid Precursor Protein Secretases / Q000037:antagonists & inhibitors; D001381:Azepines / Q000009:adverse effects* / Q000627:therapeutic use*; D003072:Cognition Disorders / Q000139:chemically induced; D057239:Early Termination of Clinical Trials; D006801:Humans; D015337:Multicenter Studies as Topic; D016032:Randomized Controlled Trials as Topic; D012878:Skin Neoplasms / Q000139:chemically induced; D017211:Treatment Failure
D000682:Amyloid; D001381:Azepines; C484278:N2-((2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl)-N1-((7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-L-alaninamide; D053829:Amyloid Precursor Protein Secretases; D000409:Alanine